Home › Agent Hub › Agent Tools › Part D coverage by drug › Basaglar

Agent Tools

Basaglar Part D coverage 2027

Basaglar is a brand of insulin glargine. What agents check before quoting it: how many 2027 Part D plans cover it, on which tier, with what restrictions and copays, by plan type, carrier and state.

Coverage at a glance

In 2027, 38 of 5,492 Medicare Part D and Medicare Advantage drug plans (0.7%) list Basaglar on their formulary, across 8 of 286 formularies. The most common placement is tier 4 (21 plans, 55.3% of those covering it). 7 of the covering plans require prior authorization (18.4%), 14 step therapy and 0 a quantity limit.

What a 30-day fill costs

7 covering plans charge a flat copay for a 30-day supply at a preferred retail pharmacy after the deductible — median $42, 1 of them $0; 31 charge coinsurance instead — median 25% of the drug's cost. Covered insulin is capped at $35 for a month's supply.

What changed since 2026

2026: 49 of 5,496 plans covered it (0.9%); 2027: 38 of 5,492 (0.7%).

Of 4,367 plans offered in both years, 0 added it to the formulary and 2 dropped it.

Among plans covering it both years, 1 moved it to a higher tier and 0 to a lower one; 0 added prior authorization and 0 removed it.

Tier placement

By plan type

By carrier

By state

Medicare usage

Medicare Part D paid for 3,061,021 30-day fills of Basaglar in 2024 for about 422,574 enrollees, at an average total cost of $212.57 per 30-day fill (CMS Part D Prescribers by Geography and Drug, national).

Related

• Lantus
• Toujeo
• Semglee

Counts are over every Medicare Advantage drug plan and stand-alone Part D plan in the CMS monthly formulary files, excluding employer plans. A plan counts as covering a drug when any strength or form of it is on the plan’s formulary; the tier, prior authorization, step therapy and quantity limit shown are the most favorable version on that formulary. Copays are for a 30-day supply at a preferred retail pharmacy after the deductible. This is a reference for licensed agents, not a plan recommendation; verify with the plan’s formulary before advising a client. Source: CMS Part D formulary files (release 10/08/2026). CMS formulary data.